Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.70 |
| ▸ | PDE6C | P51160 | 2/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2032429 | 0.95 | PDE5A (0.78) | PDE5APDE6CHDAC1HDAC2HDAC6 | |
| SCHEMBL29611957 | 0.88 | PDE5A (0.90) | PDE5APDE6CHDAC1HDAC2HDAC6 | |
| SCHEMBL146830 | 0.88 | PDE5A (0.90) | PDE5APDE6CHDAC1HDAC2HDAC6 | |
| SCHEMBL19518053 | 0.87 | PDE5A (0.66) | PDE5APDE6CHDAC1HDAC2HDAC6 | |
| SCHEMBL18069562 | 0.85 | PDE5A (0.65) | PDE5APDE6CHDAC1HDAC2HDAC6 | |
| SCHEMBL147337 | 0.82 | PDE5A (1.00) | PDE5APDE6CHDAC1HDAC2HDAC6 | |
| SCHEMBL6058528 | 0.81 | PDE5A (0.67) | PDE5APDE6C | |
| SCHEMBL18069561 | 0.80 | PDE5A (0.77) | PDE5APDE6CHDAC1HDAC2HDAC6 | |
| SCHEMBL7959160 | 0.80 | PDE5A (0.77) | PDE5APDE6CHDAC1HDAC2HDAC6 | |
| SCHEMBL2032052 | 0.79 | PDE5A (0.74) | PDE5APDE6CHDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060083714-A1 | Combination of a pde iv inhibitor and a tnf-alpha antagonist | PHARMACIA CORPORATION | 2006-04-20 | — | — | US | disclosed |
| WO-2004067006-A1 | COMBINATION OF A PDE IV INHIBITOR AND A TNF-ALPHA ANTAGONIST | PHARMACIA CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060083714-A1 | Combination of a pde iv inhibitor and a tnf-alpha antagonist | TNF, PDE4A, PDE3B | PDE5A 6/4885PDE6C 24/4885HDAC1 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.